Effect of astragalus injection on serious abdominal traumatic patients' cellular immunity.
OBJECTIVE
To explore the change of serious abdominal traumatic patients' cellular immunity and the effect of Astragalus Injection (AI) on it.


METHODS
Sixty-three serious abdominal traumatic patients were randomly assigned into two groups, the conventional group and the treated group, patients in the conventional group were given conventional treatment, while others in the treated group were given conventional treatment as the basis, with AI 20 ml was added into 250 ml of 5% glucose solution given through intravenous dripping, and then on the first day and 14th day, their T cell activated antigens as well as that of 10 healthy subjects were monitored.


RESULTS
On the first day, in the conventional group and treated group, the levels of CD(3)(+), CD(4)(+), CD(4)(+)/CD(8)(+), CD(16)(+), CD(69)(+) and CD(3)(+)/homologous leucocytic antigen-DR (HLA-DR(+)) were apparently lower than those in the healthy group (P < 0.05), while the CD(8)(+) was significantly higher than that in the healthy group (P < 0.05), and there was no significant difference between the conventional group and the treated group (P > 0.05); on the 14th days, the levels of CD(3)(+), CD(4)(+), CD(4)(+)/CD(8)(+), CD(16)(+), CD(69)(+) and CD(3)(+)/HLA-DR(+) of the treated group got closed to healthy subject value, and got even higher than those of conventional group (P < 0.05); CD(8)(+) got close to that of healthy subjects, while obviously lower than that of conventional group (P < 0.05).


CONCLUSIONS
After serious abdominal trauma, cellular immunity lowered, auxiliary use of AI was beneficial to the restoration of cellular immunity.
Wu
Jian
J
Intensive Care Unit, Putuo Hospital Affiliated to Shanghai University of TCM, Shanghai 200062.
Wang
Yi-xin
YX
Su
Wen-li
WL
Zhu
Wen-xian
WX
Lu
Jing-wei
JW
Li
Zhen-kai
ZK
D000007:Abdominal Injuries / Q000276:immunology*; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D015703:Antigens, CD / Q000032:analysis; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis; D027885:Astragalus propinquus; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D037181:Lectins, C-Type; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy; D017452:Receptors, IgG / Q000032:analysis; D016176:T-Lymphocyte Subsets; D000099192:CD69 Antigens
D000276:Adjuvants, Immunologic; D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D004365:Drugs, Chinese Herbal; D037181:Lectins, C-Type; D017452:Receptors, IgG; D000099192:CD69 Antigens